X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla Fact Sheet, Cipla Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla Fact Sheet   (CIPL)

Here is the latest financial fact sheet of Cipla. For more details, see the Cipla quarterly results and Cipla share price and chart. For a sector overview, read our pharmaceuticals sector report.

CIPLA Price History

Price Rs 541.0
Mkt Cap Rs m 435,078
Vol '000 45.4
P/E X 42.1
P/CF X 20.6
EPS (TTM) Rs 12.8
% ch % 0.4
No. of shares m 804.21
% ch week % -1.5
% ch 1-mth % -3.5
% ch 12-mth % 11.9
52 week H/L Rs 621.9/460.0
(As on Jun 23, 2017 03:37:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

CIPLA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
CIPLA EQUITY SHARE DATA
High Rs359435450753748 
Low Rs274301364369495 
Sales per share (Unadj.) Rs87.4103.1126.7141.3170.3 
Earnings per share (Unadj.) Rs14.319.217.314.718.7 
Diluted earnings per shareRs14.219.217.314.718.7 
Cash flow per share (Unadj.) Rs18.123.421.921.025.5 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs2.002.002.002.002.00 
Dividend yield (eoy) %0.60.50.50.40.3 
Book value per share (Unadj.) Rs95.1112.3125.2134.5147.6 
Adj. book value per shareRs95.0112.1125.0134.3147.4 
Shares outstanding (eoy) m802.92802.92802.92802.96803.38 
Bonus/Rights/Conversions  ---ESOPESOP 
Price / Sales ratio x3.63.63.24.03.7 
Avg P/E ratio x22.219.123.538.133.2 
P/CF ratio (eoy) x17.415.818.626.724.4 
Price / Book Value ratio x3.33.33.34.24.2 
Dividend payout %14.010.411.613.610.7 
Avg Mkt Cap Rs m254,124295,475326,829450,139499,381 
No. of employees `000NANANANA24.1 
Total wages/salary Rs m7,72510,36015,43019,73724,471 
Avg. sales/employee Rs ThNMNMNMNM5,677.3 
Avg. wages/employee Rs ThNMNMNMNM1,015.7 
Avg. net profit/employee Rs ThNMNMNMNM625.0 
CIPLA INCOME DATA
Net Sales Rs m70,20782,793101,734113,454136,783 
Other income Rs m1,3952,2212,6541,6562,089 
Total revenues Rs m71,60285,015104,388115,110138,872 
Gross profit Rs m16,61821,97921,33121,61725,011 
Depreciation Rs m3,1223,3053,7265,0475,417 
Interest Rs m3833391,4571,6831,613 
Profit before tax Rs m14,50820,55618,80016,54320,070 
Minority Interest Rs m00-159-482-494 
Prior Period Items Rs m0-62-123-253-120 
Extraordinary Inc (Exp) Rs m0398000 
Tax Rs m3,0655,4434,6344,0004,396 
Profit after tax Rs m11,44215,44913,88411,80815,059 
Gross profit margin %23.726.521.019.118.3 
Effective tax rate %21.126.524.624.221.9 
Net profit margin %16.318.713.610.411.0 
CIPLA BALANCE SHEET DATA
Current assets Rs m50,56867,84056,51475,91488,422 
Current liabilities Rs m14,13222,77625,63638,93679,089 
Net working cap to sales %51.954.430.432.66.8 
Current ratio x3.63.02.21.91.1 
Inventory Days Days96105104122102 
Debtors Days Days8174596463 
Net fixed assets Rs m35,86739,87844,45248,521110,786 
Share capital Rs m1,6061,6061,6061,6061,607 
"Free" reserves Rs m74,24887,81898,591105,484115,989 
Net worth Rs m76,38990,187100,504108,015118,574 
Long term debt Rs m3363,1793,0932,219 
Total assets Rs m93,498116,588134,032157,175208,926 
Interest coverage x38.861.613.910.813.4 
Debt to equity ratio x00000 
Sales to assets ratio x0.80.70.80.70.7 
Return on assets %12.613.511.48.68.0 
Return on equity %15.017.113.810.912.7 
Return on capital %19.523.519.315.717.4 
Exports to sales %52.653.548.641.748.9 
Imports to sales %16.115.914.014.712.6 
Exports (fob) Rs m36,92044,26249,48047,36366,837 
Imports (cif) Rs m11,33313,16214,26116,62917,270 
Fx inflow Rs m37,28244,94751,49949,10467,461 
Fx outflow Rs m13,29215,90618,94322,48324,729 
Net fx Rs m23,99029,04232,55626,62142,733 
CIPLA CASH FLOW
From Operations Rs m 17,128 13,977 15,633 11,734 17,939 
From Investments Rs m -9,651 -20,629 -12,499 -9,412 -45,795 
From Financial Activity Rs m -7,532 7,178 -2,656 1,648 31,027 
Net Cashflow Rs m -55 526 478 3,971 3,171 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 16.0%
Foreign collaborators 20.8%
Indian inst/Mut Fund 12.2%
FIIs 23.7%
ADR/GDR 1.1%
Free float 26.2%
Shareholders 161,166
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-13
E-MAIL cosecretary@cipla.com WEB www.cipla.com
TELEPHONE (022) 2482 6000 FAX (022) 2482 6893
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR V. Sankar Aiyar & Co.
CHM: Y. K. Hamied (MD) COMP SEC: Mital Sanghvi YEAR OF INC: 1935 BSE CODE: 500087 FV (Rs): 2 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   UNICHEM LAB  SUN PHARMA  NATCO PHARMA  AJANTA PHARMA  STRIDES SHASUN LTD  

Compare CIPLA With:   UNICHEM LAB  SUN PHARMA  NATCO PHARMA  AJANTA PHARMA  STRIDES SHASUN LTD  

Compare CIPLA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak End to the Week; Auto & PSU Stocks Fall(Closing)

Profit booking continued in the afternoon session in the Indian share markets amid weak European cues. At the closing bell, the BSE Sensex stood lower by 153 points.

Views on news

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

More Views on News

Most Popular

Digital Transactions were Growing Faster Before Demonetisation(Vivek Kaul's Diary)

Jun 12, 2017

Which brings us back to the basic question, why was demonetisation carried out?

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Should You Trade In Mutual Funds As You Do In Stocks?(Outside View)

Jun 10, 2017

Trading is not synonymous with mutual funds, PersonalFN explains.

Which Way Will Inflation Go?(Chart Of The Day)

Jun 10, 2017

RBI and government at loggerheads over interest rates.

More

TRACK CIPLA

MORE ON CIPLA

COMPARE CIPLA WITH

MARKET STATS